RxSight (RXST) Net Income towards Common Stockholders (2020 - 2026)

RxSight's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$15.9 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 93.94% year-over-year to -$15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.6 million (down 76.31% YoY) and the FY2025 annual result came in at -$38.9 million, down 27.48% from the prior year.
• Net Income towards Common Stockholders was -$15.9 million for Q1 2026 at RxSight, down from -$9.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $53.5 million in Q4 2022 and bottomed at -$17.6 million in Q1 2022.
• A 5-year average of -$4.1 million and a median of -$9.8 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 440.07% in 2022, while the deepest fall reached 158.57% in 2022.
• RxSight's Net Income towards Common Stockholders stood at $53.5 million in 2022, then slipped by 7.23% to $49.6 million in 2023, then plunged by 111.78% to -$5.8 million in 2024, then tumbled by 56.55% to -$9.2 million in 2025, then tumbled by 73.56% to -$15.9 million in 2026.
• Business Quant data shows RXST's Net Income towards Common Stockholders at -$15.9 million in Q1 2026, -$9.2 million in Q4 2025, and -$9.8 million in Q3 2025.